Combination strategies (including PD-1/PD-L1 inhibitors with chemotherapy, radiotherapy, angiogenesis inhibitors, or other immunomodulatory agents) have shown promise in enhancing antitumor efficacy by acting on multiple phases of the cancer–immunity cycle and remodeling the tumor microenvironment. Here, CD274 is linked to neoplasm.